SORRENTO THERAPEUTICS, INC. Form 8-K (Sept. 13, 2021)

Summary

Current report on Form 8-K for an event dated September 13, 2021, filed by Sorrento Therapeutics, Inc. The report states that on September 13, 2021 Sorrento posted an updated corporate presentation under the "Investors" section of Sorrento's website. Representatives of Sorrento will use the updated presentation in industry conferences, investor conferences and investor meetings from time to time. The presentation is filed as Exhibit 99.1, titled Corporate Presentation (September 2021), and Henry Ji signed on September 13, 2021.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Cite this document

“SORRENTO THERAPEUTICS, INC. Form 8-K (Sept. 13, 2021).” Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-srne-8-k-filed2021-09-13-0001104659-21-114999-fad5628e76/, SHA-256 38ca274e8d3c9814cce6ad115117baaf2cdd523f1077a8c6fdf6f82d1c02fc37.

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event
reported): September 13, 2021

SORRENTO THERAPEUTICS, INC.

(Exact Name of Registrant as Specified
in its Charter)

Delaware | 001-36150 | 33-0344842
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.)

4955 Directors Place

San Diego , CA 92121

(Address of Principal Executive Offices)
(Zip Code)

Registrant’s telephone number,
including area code: ( 858 ) 203-4100

N/A

(Former Name, or Former Address, if Changed
Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol | Name of each exchange on which registered
Common Stock, $0.0001 par value | SRNE | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01. Other Information .

On September 13, 2021, Sorrento Therapeutics,
Inc. (“Sorrento”) posted under the “Investors” section of Sorrento’s website at www.sorrentotherapeutics.com
an updated corporate presentation. Representatives of Sorrento will use the updated presentation in industry conferences, investor conferences
and investor meetings from time to time. A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated
herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibit.

99.1 | Sorrento Therapeutics, Inc. Corporate Presentation (September 2021).
104 | Cover Page interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SORRENTO THERAPEUTICS, INC.
Date: September 13, 2021 | By: | /s/ Henry Ji, Ph.D.
Name: Henry Ji, Ph.D.
Title: Chairman, President and Chief Executive Officer

File and source

File: SEC_SRNE_8-K_filed2021-09-13_0001104659-21-114999.htm
Size: 25,559 bytes
SHA-256: 38ca274e8d3c9814cce6ad115117baaf2cdd523f1077a8c6fdf6f82d1c02fc37
Our copy: SEC_SRNE_8-K_filed2021-09-13_0001104659-21-114999.htm
Original: www.sec.gov